Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | CJC-1295 (no DAC) | CJC-1295 DAC |
|---|---|---|
| Class | GH secretagogue (GHRH analogue) | Long-acting GH secretagogue |
| Research category | GH / IGF-1 axis | GH / IGF-1 axis |
| Evidence level | Low | Low |
| Overall status | Not approved — research | Not approved — research |
| FDA | Not approved | Not approved |
| EMA | Not approved | Not approved |
| WADA | Prohibited — S2 | Prohibited — S2 |
| Mechanism studied | CJC-1295 → GHRH receptor → Pituitary GH pulse → Hepatic IGF-1 | CJC-1295 DAC → Albumin binding → GHRH receptor → Sustained IGF-1 |
| Molecular weight | — | — |
| Sizes in stock | 10mg | Not currently listed |
Where the research overlaps
Both compounds are studied within GH Axis research. CJC-1295 (no DAC) is classed as gh secretagogue (ghrh analogue), while CJC-1295 DAC is long-acting gh secretagogue. Evidence is rated low for CJC-1295 (no DAC) and low for CJC-1295 DAC.
For a full write-up, read GHRH Analogues: Tesamorelin, Sermorelin and CJC-1295.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.